Characterization of classical and nonclassical fabry disease: A multicenter study, J. Am. Soc. Nephrol, vol.28, pp.1631-1641, 2017. ,
Prevalence of lysosomal storage disorders, Jama, vol.281, pp.249-254, 1999. ,
Newborn screening for Fabry disease in Japan: Prevalence and genotypes of Fabry disease in a pilot study, J. Hum. Genet, vol.58, 2013. ,
Neonatal screening for lysosomal storage disorders: Feasibility and incidence from a nationwide study in Austria, Lancet, vol.379, pp.335-341, 2012. ,
High incidence of later-onset Fabry disease revealed by newborn screening, Am. J. Hum. Genet, vol.79, pp.31-40, 2006. ,
Lysosomal storage disorder screening implementation: Findings from the first six months of full population pilot testing in Missouri, J. Pediatrics, vol.166, pp.172-177, 2015. ,
High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population, Circ. Cardiovasc. Genet, vol.2, pp.450-456, 2009. ,
Biomarkers for diagnosing and staging of Fabry disease, Curr. Med. Chem, vol.25, pp.1530-1537, 2018. ,
Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry, Genet. Med. Off. J. Am. Coll. Med Genet, vol.11, pp.790-796, 2009. ,
Difficulties and barriers in diagnosing Fabry disease: What can be learnt from the literature?, Expert Opin. Med. Diagn, vol.7, pp.589-599, 2013. ,
Fabry's disease, J. Neurol. Sci, vol.344, pp.5-19, 2014. ,
Mutations in the GLA Gene and LysoGb3: Is it really Anderson-Fabry disease?, Int. J. Mol. Sci, vol.19, 2018. ,
Biochemical and genetic diagnosis of Fabry disease, Fabry Disease: Perspectives from 5 Years of FOS, 2006. ,
Fabry's disease: Enzymatic diagnosis of hemizygotes and heterozygotes: ?-galactosidase activities in plasma, serum, urine, and leukocytes, J. Lab. Clin. Med, vol.81, pp.157-171, 1973. ,
Enzymatic diagnosis in dried blood spots on filter paper, Clin. Chim. Acta, vol.1, pp.195-196, 2001. ,
A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease, vol.3, pp.2741-2784, 2001. ,
Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry, FEBS Lett, vol.515, pp.171-176, 2002. ,
Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease, Mol. Genet. Metab, vol.121, pp.320-324, 2017. ,
Rapid quantitation of globotriaosylceramide in human plasma and urine: A potential application for monitoring enzyme replacement therapy in Anderson-Fabry disease, Rapid Commun. Mass Spectrom, vol.16, pp.1507-1514, 2002. ,
Elevated globotriaosylsphingosine is a hallmark of Fabry disease, Proc. Natl. Acad. Sci, vol.105, pp.2812-2817, 2008. ,
A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease, Mol. Genet. Metab, vol.122, pp.121-125, 2017. ,
Fabry's disease, Lancet, vol.372, pp.1427-1435, 2008. ,
Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease, J. Inherit. Metab. Dis, vol.30, 2007. ,
Fabry disease: A review of current enzyme replacement strategies. Expert Opin, Orphan Drugs, vol.3, pp.1319-1330, 2015. ,
Enzyme replacement therapy in Fabry disease: A randomized controlled trial, Jama, vol.285, pp.2743-2749, 2001. ,
A review in Fabry disease, Drugs, vol.79, pp.543-554, 2019. ,
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors, PLoS ONE, vol.12, 2017. ,
The large phenotypic spectrum of Fabry disease requires graduated diagnosis and personalized therapy: A meta-analysis can help to differentiate missense mutations, Int. J. Mol. Sci, vol.17, 2010. ,
Time delays in the diagnosis and treatment of Fabry disease, Int. J. Clin. Pract, vol.71, 2017. ,
Metabolic causes of nonimmune hydrops fetalis: A next-generation sequencing panel as a first-line investigation, Clin. Chim. Acta Int. J. Clin. Chem, vol.481, pp.1-8, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02356382
Urinary metabolic phenotyping of mucopolysaccharidosis type I combining untargeted and targeted strategies with data modeling, Clin. Chim. Acta Int. J. Clin. Chem, vol.475, pp.7-14, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02445369
Omics-based strategies in precision medicine: Toward a paradigm shift in inborn errors of metabolism investigations, Int. J. Mol. Sci, vol.17, 1555. ,
URL : https://hal.archives-ouvertes.fr/hal-02452350
Clinical metabolomics: The new metabolic window for inborn errors of metabolism investigations in the post-genomic era, Int. J. Mol. Sci, vol.17, 1167. ,
URL : https://hal.archives-ouvertes.fr/hal-02453944
Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: Preliminary findings, Mol. Biosyst, vol.9, pp.1162-1168, 2013. ,
Elevated inflammatory plasma biomarkers in patients with Fabry disease: A critical link to heart failure with preserved ejection fraction, J. Am. Heart Assoc, vol.7, 2018. ,
Early markers of Fabry disease revealed by proteomics, Mol. Biosyst, vol.11, pp.1543-1551, 2015. ,
The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: Evidence of presymptomatic kidney disease in pediatric Fabry and Type-I diabetic patients, J. Proteome Res, vol.12, 2013. ,
Fabry disease: Characterisation of the plasma proteome pre-and post-enzyme replacement therapy, J. Med Genet, vol.54, pp.771-780, 2017. ,
Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities, Proc. Natl. Acad. Sci, vol.104, pp.2873-2878, 2007. ,
A human stem cell model of Fabry disease implicates LIMP-2 accumulation in cardiomyocyte pathology, Stem Cell Rep, vol.13, pp.380-393, 2019. ,
Generation of GLA-knockout human embryonic stem cell lines to model autophagic dysfunction and exosome secretion in Fabry disease-associated hypertrophic cardiomyopathy, vol.8, p.327, 2019. ,
Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: Results from the SOPHIA study, Mol. Genet. Metab, vol.126, pp.169-182, 2019. ,
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease, J. Med. Genet, vol.57, pp.38-47, 2020. ,
Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY, Orphanet J. Rare Dis, vol.13, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02086919
A chemometrics toolbox based on projections and latent variables, J. Chemom, vol.28, pp.332-346, 2014. ,
Lyso-Gb3) as a biomarker for cardiac variant (N215S) Fabry disease, J. Inherit. Metab. Dis, vol.41, pp.239-247, 2018. ,
Fibroblast growth factor regulation of neovascularization, Curr. Opin. Hematol, vol.15, pp.215-220, 2008. ,
Possible role of transforming growth factor-beta1 and vascular endothelial growth factor in Fabry disease nephropathy, Int. J. Mol. Med, vol.30, pp.1275-1280, 2012. ,
Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer, Cancer Sci, vol.107, pp.1141-1150, 2016. ,
The FGF2 aptamer inhibits the growth of FGF2-FGFR pathway driven lung cancer cells, Biochem. Biophys. Res. Commun, vol.503, pp.1330-1334, 2018. ,
Globotriaosylceramide induces endothelial dysfunction in fabry disease, Arterioscler. Thromb. Vasc. Biol, vol.34, 2014. ,
Fabry disease and incidence of cancer, Orphanet J. Rare Dis, vol.12, 2017. ,
Fabry disease: Four case reports of meningioma and a review of the literature on other malignancies, Mol. Genet. Metab. Rep, vol.11, pp.75-80, 2017. ,
Contribution of inflammatory pathways to Fabry disease pathogenesis, Mol. Genet. Metab, vol.122, pp.19-27, 2017. ,
Dysregulated autophagy contributes to podocyte damage in Fabry's disease, PLoS ONE, vol.8, 2013. ,
Autophagosome maturation is impaired in Fabry disease, Autophagy, vol.6, pp.589-599, 2010. ,
Evaluation of proinflammatory prognostic biomarkers for fabry cardiomyopathy with enzyme replacement therapy, Can. J. Cardiol, vol.32, p.1221, 2016. ,
Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease, Am. J. Cardiol, vol.111, pp.111-117, 2013. ,
High-sensitivity troponin: A clinical blood biomarker for staging cardiomyopathy in Fabry disease, J. Am. Heart Assoc, vol.5, 2016. ,
Value of cardiac biomarker measurement in the differential diagnosis of infiltrative cardiomyopathy patients with preserved left ventricular systolic function, J. Thorac. Dis, vol.10, pp.4966-4975, 2018. ,
The class III kinase Vps34 promotes T lymphocyte survival through regulating IL-7Ralpha surface expression, J. Immunol, vol.187, pp.5051-5061, 2011. ,
IL-7 in human health and disease, Semin. Immunol, vol.24, pp.218-224, 2012. ,
Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity, J. Inherit. Metab. Dis, vol.43, pp.334-347, 2020. ,
, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2020 by the authors. Licensee MDPI